TORONTO, Aug. 14 /CNW/ - Predictive medicine company PreMD Inc. (TSX:
PMD; Amex: PME) today announced that a scientific abstract entitled 'Increased
Skin Cholesterol Identifies Individuals at Increased Cardiovascular Risk: The
Predictor of Advanced Subclinical Atherosclerosis (PASA) Study' has been
accepted for presentation at the American Heart Association (AHA) Scientific
"We are pleased that our abstract was accepted for presentation at this
conference. The annual AHA meeting is one of the most important conferences
worldwide where cardiovascular research and innovations are discussed and
examined," said Brent Norton, president and chief executive officer of PreMD
Inc. "Following the announcement of our recent partnership with AstraZeneca,
this news highlights our progress and underscores our commitment to clinical
research and advancement. We, along with our collaborators, are very
encouraged by the results linking skin cholesterol levels with increased
cardiovascular disease risk. This acceptance further strengthens our clinical
data and our PREVU(*) product."
The lead author on the PASA abstract is Dr. James H. Stein from the
University of Wisconsin. The co-authors of the study are: Dr. Wendy S. Tzou,
University of Pennsylvania School of Medicine; Dr. Jeanne M. DeCara,
University of Chicago Pritzker School of Medicine; Dr. Alan T. Hirsch,
University of Minnesota School of Public Health and Minneapolis Heart
Institution Foundation; Dr. Emile R. Mohler III, University of Pennsylvania
School of Medicine; Dr. Pamela Ouyang, John Hopkins University School of
Medicine; Dr. Gregory L Pearce, Innovative Data Resources; and Dr. Michael H
Davidson, Radiant Research.
The AHA Scientific Sessions conference takes place November 2-7, 2007 in
About PreMD Inc.
PreMD Inc. is a leader in predictive medicine, dedicated to developing
rapid, non-invasive tests for the early detection of life-threatening
diseases. PreMD's cardiovascular products are branded as PREVU(*) Skin
Cholesterol Test, to be marketed and distributed by AstraZeneca. The company's
cancer tests include ColorectAlert(TM), LungAlert(TM) and a breast cancer
test. PreMD's head office is located in Toronto, Ontario and its research and
product development facility is at McMaster University in Hamilton, Ontario.
For further information, please visit www.premdinc.com. For more information
about PREVU(*), please visit www.prevu.com.
This press release contains forward-looking statements. These statements
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include, among
others, the success of a plan for regaining compliance with certain continued
listing standards of the American Stock Exchange, successful development or
marketing of the Company's products, the competitiveness of the Company's
products if successfully commercialized, the lack of operating profit and
availability of funds and resources to pursue R&D projects, the successful and
timely completion of clinical studies, product liability, reliance on
third-party manufacturers, the ability of the Company to take advantage of
business opportunities, uncertainties related to the regulatory process, and
general changes in economic conditions.
In addition, while the Company routinely obtains patents for its products
and technology, the protection offered by the Company's patents and patent
applications may be challenged, invalidated or circumvented by our competitors
and there can be no guarantee of our ability to obtain or maintain patent
protection for our products or product candidates.
Investors should consult the Company's quarterly and annual filings with
the Canadian and U.S. securities commissions for additional information on
risks and uncertainties relating to the forward-looking statements. Investors
are cautioned not to rely on these forward-looking statements. PreMD is
providing this information as of the date of this press release and does not
undertake any obligation to update any forward-looking statements contained in
this press release as a result of new information, future events or otherwise.
%SEDAR: 00007927E %CIK: 0001179083
For further information:
For further information: Brent Norton, President and CEO, Tel: (416)
222-3449 ext. 22, Email: firstname.lastname@example.org; Ron Hosking, Vice President
Finance and CFO, Tel: (416) 222-3449 ext. 24, Email: email@example.com;
Michelle Rabba, Manager, Corporate Communications, Tel: (416) 222-3449 ext.
25, Email: firstname.lastname@example.org